Business
Adagio Medical Reports First Quarter 2026 Results and Meaningful Clinical Progress
LAGUNA HILLS, Calif., May 12, 2026--Adagio Medical Holdings, Inc (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the first quarter ended March 31, 2026.
About this update from Adagio Medical Holdings, Inc
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":480,"url":"https://media.zenfs.com/en/business-wire.com/935c8fc1f069e01213395531c093aca7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/dEH1aGNKRctv5n.AHvxo6Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTk2MA--/https://media.zenfs.com/en/business-wire.com/935c8fc1f069e01213395531c093aca7","width":480,"height":480},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/ipMZZFTQ3HhnpFivR0i3yw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTY0MA--/https://media.zenfs.com/en/business-wire.com/935c8fc1f069e01213395531c093aca7","width":480,"height":480}},"lazy":false},{"type":"text","content":"Advancing Toward Submission for PMA Approval Following Late-Breaking FULCRUM-VT Data","length":84,"tagName":"p","attribs":{}},{"type":"text","content":"LAGUNA HILLS, Calif., May 12, 2026--(BUSINESS WIRE)--Adagio Medical Holdings, Inc (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the first quarter ended March 31, 2026.","length":319,"tagName":"p"},{"type":"text","content":"Recent Business Highlights:","length":27,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Pivotal results from the FULCRUM-VT trial presented in late-breaking session at Heart Rhythm Society 2026 – the first large-scale, rigorously executed pivotal trial in patients with both ischemic and non-ischemic cardiomyopathies—which demonstrated 84% freedom from implantable cardioverter defibrillator ("ICD") shock at six months, a promising safety profile with 2.4% protocol-defined Major Adverse Events, and a 72% discontinuation or reduced dose of antiarrhythmic drugs, as well as equivalent results across both ischemic and non-ischemic cardiomyopathy patients with the Company's proprietary Ultra-Low Temperature Ablation ("ULTA") technology","length":674,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Received Food and Drug Administration ("FDA") Investigational Device Exemption ("IDE") approval to expand the FULCRUM-VT trial to evaluate the safety and effectiveness of the next-generation vCLAS Ultra System, which is designed to b...